Orchid Pharma Limited (ORCHPHARMA) — Board Meeting

· NSE 🟡 Notable Neutral
📢 Key Event
Shareholders approved revised QIP fund allocation at AGM on September 20, 2025.
🔄 What Changed
Revised allocation of QIP proceeds among specified objects after shareholder approval.
🔮 What's Next
Commercial operations at Jammu facility expected to commence by February 2027.
💡 Investor Takeaway
Shareholders approved reallocating QIP funds, confirming proper use of capital with no material deviations.

Orchid Pharma disclosed a Monitoring Agency Report confirming proper utilization of Rs. 400 crores raised via Qualified Institutional Placement, with shareholder approval for revised fund allocation after an AGM on September 20, 2025. The report validates compliance with SEBI norms and shows no material deviations in fund usage.

📄 View Original Announcement (PDF)

About Orchid Pharma Limited (ORCHPHARMA)

Healthcare · Pharmaceuticals & Biotechnology · Listed on NSE

Market Cap: ₹3,614.24 Cr P/E: 32.3

View full ORCHPHARMA stock details →

📡 Get AI alerts when ORCHPHARMA files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track ORCHPHARMA — Free

📊 More ORCHPHARMA filings

See all ORCHPHARMA filings →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

📡 Get AI alerts when ORCHPHARMA files new disclosures

Track ORCHPHARMA filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track ORCHPHARMA — Free

Free account · 2 AI queries/day